PM 54
Alternative Names: PM-54Latest Information Update: 01 Jul 2026
At a glance
- Originator PharmaMar
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; RNA polymerase II inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 21 May 2026 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT07644039)
- 22 Apr 2026 Pharmacodynamics data from the preclinical studies in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 06 Apr 2026 Pharma Mar plans a phase I/II trial for Cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain, United Kingdom and USA (Infusion), in April 2026 (CTIS2025-523774-16-00) (EUCT2025-523774-16-00)